I have persistent symptoms after COVID-19 infection or confirmed long COVID, Should I use low-dose naltrexone (LDN) (1.5–6 mg) or continue without LDN?
Summary
Summary of your value assessment
Below is a listing of the arguments for and against starting or trying LDN, together with your value assessment (where 0 means you are "dead" and 100 you are in "perfect health"). The results are uncertain about the benefits and harms of LDN among people with post COVID-19 condition. You may trial LDN if you place a relatively higher value on some desirable outcomes and a relatively lower value on the undesirable outcomes.
For Taking LDN
Against Taking LDN
Move any outcomes that you do not want to consider in your decision to the box below
Drag and drop outcomes here
Conditional Recommendation from the Canadian Guidelines for Post COVID-19 Condition (CAN-PCC)
The CAN-PCC Collaborative suggests not using low-dose naltrexone for adults with post COVID-19 condition.
Remarks: In light of very limited evidence for the potential benefits or harms of low-dose naltrexone among people with post COVID-19 condition, some people with post COVID-19 condition may still decide to trial low-dose naltrexone if theyplace a relatively higher value on some desirable outcomes and a relatively lower value on the undesirable outcomes.
Remarks: In light of very limited evidence for the potential benefits or harms of low-dose naltrexone among people with post COVID-19 condition, some people with post COVID-19 condition may still decide to trial low-dose naltrexone if theyplace a relatively higher value on some desirable outcomes and a relatively lower value on the undesirable outcomes.
Your decision
To prepare for the meeting with your healthcare professional, please select the statement that describes your current decision the best
Please write down in the box below any other relevant issues that influenced your decision but were not included in this decision aid. You may also note other issues that you would like to discuss.
Type here